Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19

• Published in: Cardiovascular drugs and therapy Vol. 36; no. 6; pp. 1165 - 1173
• Main Authors: Choi, Daein, Chen, Qinzhong, Goonewardena, Sascha N., Pacheco, Hannah, Mejia, Priscilla, Smith, Robin L., Rosenson, Robert S.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.12.2022; Springer Nature B.V
• Subjects: Cardiology; Cardiovascular disease; Cardiovascular diseases; Clinical trials; Comorbidity; Coronary artery disease; Coronary vessels; Coronaviruses; COVID-19; Death; Health hazards; Heart diseases; Hospitalization; Immune response; Immunomodulation; Lipids; Medicine; Medicine & Public Health; Mortality; Original; Original Article; Patients; Risk management; Statins; Statistical models; Subgroups; Vein & artery diseases; Viral diseases; COVID-19; Statin; Coronary artery disease; Mortality
• ISSN: 0920-3206; 1573-7241
• DOI: 10.1007/s10557-021-07263-2

Purpose COVID-19 is characterized by dysfunctional immune responses and metabolic derangements, which in some, lead to multi-organ failure and death. Statins are foundational lipid-lowering therapeutics for cardiovascular disease and also possess beneficial immune-modulating properties. Because of these immune-modulating properties, some have suggested their use in COVID-19. We sought to investigate the association between statin use and mortality in patients hospitalized with COVID-19. Methods Five thousand three hundred seventy-five COVID-19 patients admitted to Mount Sinai Health System hospitals in New York between February 27, 2020, and December 3, 2020, were included in this analysis. Statin use was classified as either non-user, low-to-moderate-intensity user, or high-intensity user. Multivariate Cox proportional hazards models were used to evaluate in-hospital mortality rate. Considered covariates were age, sex, race, and comorbidities. Results Compared to non-statin users, both low-to-moderate-intensity (adjusted hazard ratio; aHR 0.62, 95% confidential intervals; CI 0.51–0.76) and high-intensity statin users (aHR 0.53, 95% CI 0.43–0.65) had a reduced risk of death. Subgroup analysis of 723 coronary artery disease patients showed decreased mortality among high-intensity statin users compared to non-users (aHR 0.51, 95% CI 0.36–0.71). Conclusions Statin use in patients hospitalized with COVID-19 was associated with a reduced in-hospital mortality. The protective effect of statin was greater in those with coronary artery disease. These data support continued use of statin therapy in hospitalized patients with COVID-19. Clinical trials are needed to prospectively determine if statin use is effective in lowering the mortality in COVID-19 and other viral infections.